21763-00-8

Usage

Uses

Used in Pharmaceutical Industry:
(1-Bromo-3-chloropropyl)benzene is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the formation of complex molecular structures that can exhibit therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical sector, (1-Bromo-3-chloropropyl)benzene serves as an intermediate in the production of various agrochemicals, potentially aiding in the development of new pesticides or herbicides.
Used in Polymer Production:
(1-Bromo-3-chloropropyl)benzene is utilized in the manufacturing process of polymers, where it may contribute to the creation of polymers with specific properties required for various applications.
Used as a Solvent in Chemical Processes:
(1-Bromo-3-chloropropyl)benzene also functions as a solvent in a range of chemical processes, providing a medium for reactions to occur and facilitating the synthesis of desired products.
Safety Considerations:
Despite its low toxicity and lack of significant environmental hazards, (1-Bromo-3-chloropropyl)benzene should be handled with care due to its potential to cause irritation to the skin, eyes, and respiratory system. Proper safety protocols must be followed to ensure the well-being of those who work with (1-Bromo-3-chloropropyl)benzene.

Upstream product

• 18776-12-0 3-chloro-1-phenyl-propan-1-ol 
• 104-52-9 phenylpropyl chloride 
• 94-36-0 dibenzoyl peroxide 
• 936-59-4 3-chloropropiophenone 

Downstream Products

• 4446-91-7 3-chloro-1-methoxy-1-phenylpropane 
• 200004-18-8 1-(3-chloro-1-phenylpropoxy)-4-nitrobenzene 
• 200004-15-5 1-phenyl-1-(4-methylphenoxy)-3-chloropropane 
• 81347-68-4 1-chloro-3-phenyl-3-(4-trifluoromethylphenoxy)propane 
• 745817-26-9 1-phenyl-1-(2,4-difluorophenoxy)-3-chloropropane 
• 745817-25-8 1-phenyl-1-(2,4-dichlorophenoxy)-3-chloropropane 
• 385436-87-3 [4-(3-chloro-1-phenyl-propoxy)-phenyl]-phenyl-methanone 
• 745817-24-7 1-phenyl-1-(4-chlorophenoxy)-3-chloropropane 
• 53179-07-0 nisoxetine 
• 17382-10-4 1,1-dimethyl 2-phenylcyclobutane-1,1-dicarboxylate 
• 56161-70-7 N-methyl-3-phenoxy-3-phenyl-1-propylamine 
• 56225-81-1 N,N-dimethyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)-1-propylamine 
• 54910-89-3 FLUOXETINE 
• 21763-01-9 1-phenyl-1-phenoxy-3-chloropropane 

Relevant academic research and scientific papers

Sulphide as a leaving group: Highly stereoselective bromination of alkyl phenyl sulphides

A conceptionally novel nucleophilic substitution approach to synthetically important alkyl bromides is presented. Using molecular bromine (Br2), readily available secondary benzyl and tertiary alkyl phenyl sulphides are converted into the corresponding bromides under exceptionally mild, acid- and base-free reaction conditions. This simple transformation allows the isolation of elimination sensitive benzylic β-bromo carbonyl and nitrile compounds in mostly high yields and purities. Remarkably, protic functionalities such as acids and alcohols are tolerated. Enantioenriched benzylic β-sulphido esters, readily prepared by asymmetric sulpha-Michael addition, produce the corresponding inverted bromides with high stereoselectivities, approaching complete enantiospecificity at -40 °C. Significantly, the reported benzylic β-bromo esters can be stored without racemisation for prolonged periods at -20 °C. Their synthetic potential was demonstrated by the one-pot preparation of γ-azido alcohol (S)-5 in 90% ee. NMR studies revealed an initial formation of a sulphide bromine adduct, which in turn is in equilibrium with a postulated dibromosulphurane intermediate that undergoes C-Br bond formation.

Method for synthesizing alkyne through catalytic asymmetric cross coupling (by machine translation)

The invention belongs to the field of, asymmetric synthesis, and discloses a method for catalyzing asymmetric cross- coupling to synthesize: an alkyne, and the L method comprises, the following steps, of A: preparing B a cuprous, salt and C a: ligand; preparing a catalyst; adding a base; reacting the compound with the compound with the compound; and reacting the compound with the compound. Of these, one of them, X is selected from the group consisting of, R halogens. 1 Optionally substituted heteroarylsulfonylcyanamide groups selected from the, group consisting, of optionally substituted, phenyl groups In-flight vehicle, R6 Trialkyl silyl groups or alkyl radicals, R2 Cycloalkyl radicals optionally substituted with an, optionally substituted alkyl, (CH radical2 )n R4 Multi,layer chain, n＝0-10,R saw blade4 A group selected, from, the group consisting of phenyl, alkenyl, aralkynyls, noonyloxy,and, noonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulfonylsulphonylsulphonylsulphonylsulphonylsulphonylsulphonylsulphonylsulphonylsulphonylsulphonylphenyl disiloxy-radicals. R3 A ligand, selected from hydrogen or any of the functional groups, is selected from the group consisting of, hydrogen and any L other functional group. The method, R disclosed by the, A invention has the, advantages of good catalytic, R ’ effect, wide application range. and high catalytic efficiency, and the, method disclosed by the, invention has the. advantages of good catalytic effect, wide application range and high catalytic efficiency. (by machine translation)

DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS

The disclosure is directed to novel dopamine D3 receptor antagonists, processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, including treating drug dependency and psychosis.

Synthesis and in silico evaluation of novel compounds for PET-based investigations of the norepinephrine transporter

Since the norepinephrine transporter (NET) is involved in a variety of diseases, the investigation of underlying dysregulation-mechanisms of the norepinephrine (NE) system is of major interest. Based on the previously described highly potent and selective NET ligand 1-(3-(methylamino)-1-phenylpropyl)-3-phenyl-1,3-dihydro-2H-benzimidaz- ol-2-one (Me@APPI), this paper aims at the development of several fluorinated methylaminebased analogs of this compound. The newly synthesized compounds were computationally evaluated for their interactions with the monoamine transporters and represent reference compounds for PET-based investigation of the NET.

Molecular basis for selective serotonin reuptake inhibition by the antidepressant agent fluoxetine (Prozac)

Inhibitors of the serotonin transporter (SERT) are widely used antidepressant agents, but the structural mechanism for inhibitory activity and selectivity over the closely related norepinephrine transporter (NET) is not well understood. Here we use a combination of chemical, biological, and computational methods to decipher the molecular basis for high-affinity recognition in SERT and selectivity over NET for the prototypical antidepressant drug fluoxetine (Prozac; Eli Lilly, Indianapolis, IN). We show that fluoxetine binds within the central substrate site of human SERT, in agreement with recent X-ray crystal structures of LeuBAT, an engineered monoamine-like version of the bacterial amino acid transporter LeuT. However, the binding orientation of fluoxetine is reversed in our experimentally supported model comparedwith the LeuBAT structures, emphasizing the need for careful experimental verification when extrapolating findings from crystal structures of bacterial transporters to human relatives. We find that the selectivity of fluoxetine and nisoxetine, a NET selective structural congener of fluoxetine, is controlled by residues in different regions of the transporters, indicating a complex mechanism for selective recognition of structurally similar compounds in SERT and NET. Our findings add important new information on the molecular basis for SERT/NET selectivity of antidepressants, and provide the first assessment of the potential of LeuBAT as a model system for antidepressant binding in human transporters, which is essential for future structure-based drug development of antidepressant drugs with fine-tuned transporter selectivity. Copyright

MULTITARGET SUBSTITUTED BIPHENYL DIOL DERIVATIVES

Biphenyl diol compounds of formula (I) and their use as a medicament to suppress tumor growth and/or prevent recurrence or metastasis or to treat a cancer selected from the group consisting of brain, bone, colon, ovary, pancreas, prostate, skin, lung, and

Multitarget substituted biphenyl diol derivatives

New multitarget biphenyl diol compounds and their use as a medicament to suppress tumor growth and/or prevent recurrence or metastasis or to treat a cancer selected from the group consisting of brain, bone, colon, ovary, pancreas, prostate, skin, lung, an

Direct and selective benzylic oxidation of alkylarenes via C-H abstraction using alkali metal bromides

A direct benzylic oxidation of alkylarenes via C-H bond abstraction was developed using alkali metal bromides and oxidants under mild conditions. This reaction proceeded with excellent selectivity by thermal oxidation or photooxidation to provide a broad range of carbonyl compounds containing electron-deficient aryl carbonyl compounds in high yields.

1-[(3-Aryloxy-3-aryl)propyl]-1H-imidazoles, new imidazoles with potent activity against Candida albicans and dermatophytes. Synthesis, structure-activity relationship, and molecular modeling studies

New 1-[(3-aryloxy-3-aryl)propyl]-1H-imidazoles were synthesized and evaluated against Candida albicans and dermatophytes in order to develop structure-activity relationships (SARs). Against C. albicans the new imidazoles showed minimal inhibitory concentrations (MICs) comparable to those of ketoconazole, miconazole, and econazole, and were more potent than fluconazole. Several derivatives (10, 12, 14, 18-20, 24, 28, 29, 30, and 34) turned out to be potent inhibitors of C. albicans strains resistant to fluconazole, with MIC values less than 10 μg/mL. Against dermatophytes strains, compounds 20, 25, and 33 (MIC ≤ 5 μg/mL) were equipotent to ketoconazole, econazole, and miconazole. SARs of imidazoles 10-44 were rationalized with reasonable accuracy by a previously developed quantitative pharmacophore for antifungal agents.

Imidazole analogues of fluoxetine, a novel class of anti-Candida agents

Imidazole analogues of fluoxetine have been obtained by replacing the methylamino terminus of aminopropane chain with the imidazole ring. The newly designed imidazoles showed potent anti-Candida activity, superior to those of miconazole and other antifungal agents of clinical interest. 1-(4-Chlorophenyl)-l-(2,4-dichlorophenoxy)-3-(1H-imidazol-1-yl)propane (16), the most active among test imidazoles, Was about 2-fold more active and as much less cytotoxic than miconazole. High increase of activity was observed with methyl, nitro, fluorine, and chlorine (Cl > F > CH3 > NO2 > CF3).